Process Challenges of Antibody-Drug Conjugates

摘要

With two products now on the market, and a host of others in clinical trials, antibody-drug conjugates (ADCs) are slowly becoming a big business. Designed to deliver extremely active cytotoxic drugs that are otherwise undosable, they take advantage ofthe targeting ability of a specifically designed monoclonal antibody (MAb) to "shield" a highly potent API (HPAPI) as it travels through a patient's bloodstream after administration. Once the antibody reaches its target on the cancer cell, it will release the payload, ready to damage or kill the cancer cell.